

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



MicroPort NeuroTech Limited

微創腦科學有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2172)

POSITIVE PROFIT ALERT

This announcement is made by MicroPort NeuroTech Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) is pleased to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on the preliminary assessment of the unaudited consolidated management accounts of the Group and other currently available information for the year ended December 31, 2023 (the “**Reporting Period**”), the Group is expected to record an adjusted net profit¹ of not less than RMB178 million, representing an increase of at least approximately 36% as compared to that of the year ended December 31, 2022 (the “**Previous Year**”). Compared with the net loss of RMB24.68 million recorded in the Previous Year, the Group is expected to achieve a turnaround in net profit and strong growth during the Reporting Period.

Based on currently available information, the Board considers that the aforementioned expected substantial increase in the profit of the Group is principally attributable to the following reasons:

- (1) Multiple market-share leading products (including Tubridge® Flow-diverting Stent, Bridge® Rapamycin Target Eluting Vertebral Artery Stent System and NUMEN® Coil Embolization System, etc.) continued to expand into uncovered hospital and low-tier markets, further consolidated the competitive advantages and achieved significant growth in revenue;

¹ The Company used “adjusted net profit” as non-HKFRS measures, eliminating impacts of profit/loss of associates and certain non-cyclical or one-time expense items (including accrued interest expenses on preferred shares, listing expenses, share-based payment expenses and potential impairment loss on assets, etc.).

- (2) The newly approved products in 2022 (including Neurohawk® Stent Thrombectomy Device and Diveer® Intracranial Balloon Dilatation Catheter, etc.) accelerated hospital admission and contributed to the growth of the Group’s revenue;
- (3) Through implementation of supply chain improvement and cost saving measures, the Group continued to improve its gross profit margin and operating efficiency, resulting in a significant increase in profitability.

As at the date of this announcement, the Company is still in the process of preparing and finalizing the annual results of the Group for the year ended December 31, 2023 (the “**2023 Annual Results**”). The information contained in this announcement is only a preliminary assessment made by the Board based on the latest management accounts of the Group which have not been audited or reviewed by the independent auditors or the audit committee of the Company. Shareholders and potential investors of the Company are advised to read the Company’s announcement of the 2023 Annual Results carefully, which is expected to be published by the end of March 2024.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
MicroPort NeuroTech Limited
Dr. Chang Zhaohua
Chairman

Hong Kong, January 7, 2024

As at the date of this announcement, the executive Directors are Mr. Xie Zhiyong and Mr. Wang Yiqun Bruce, the non-executive Directors are Dr. Chang Zhaohua, Mr. Sun Qingwei, Mr. Wang Lin and Ms. Wu Xia, and the independent non-executive Directors are Dr. Xu Yi, Dr. Zhang Haixiao and Mr. Siu Chi Hung.